**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 11511**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (5): Colorectal cancer

**Early-onset colorectal cancer: A separate subset of colorectal cancer**

Osorio Silla I *et al*. Early-onset colorectal cancer

Irene Osorio Silla, Daniel Rueda, Yolanda Rodríguez, Jose Luis García, Felipe de la Cruz Vigo, José Perea García

**Irene Osorio Silla, Felipe de la Cruz Vigo, José Perea García**, Department of Surgery, 12 de Octubre University Hospital, 28048 Madrid, Spain

**Daniel Rueda**, Molecular Biology Laboratory, 12 de Octubre University Hospital, 28048 Madrid, Spain

**Yolanda Rodríguez**, Department of Pathology, 12 de Octubre University Hospital, 28048 Madrid, Spain

**Jose Luis García,** Centre for Cancer Research, Medical University of Salamanca, 37008 Salamanca, Spain

**Author contributions:** Rueda D, Rodríguez Y, García JL acquired and analyzed data; Cruz Vigo F, Perea Garcia J revised the article; Osorio Silla I designed and wrote the article.

**Supported by** Project PI10/0683 from the Spanish Ministry of Health and Consumer Affairs

**Correspondence to: José Perea García, MD, PhD,** Department of Surgery, 12 de Octubre University Hospital, Avd. de Córdoba S/N, 28048 Madrid, Spain. [josepereag@hotmail.com](mailto:josepereag@hotmail.com)

**Telephone:** +34-6-69332053 **Fax:** +34-6-69332053

**Received:** May 25, 2014 **Revised:** July 27, 2014

**Accepted:** November 7, 2014

**Published online:**

**Abstract**

Colorectal cancer (CRC) has a great impact on the world population. With increasing frequency, CRC is described according to the presenting phenotype, based on its molecular characteristics. Classification of CRC tumors according to their genetic and/or epigenetic alterations is not only important for establishing the molecular based of the disease, but also for predicting patient outcomes and developing more individualized treatments. Early-onset CRC is a heterogeneous disease, with a strong familial component, although the disease is sporadic in an important proportion of cases. Different molecular alterations appear to contribute to the apparent heterogeneity of the early-onset population and subgroups can be distinguished with distinct histopathological and familial characteristics. Moreover, compared with late-onset CRC, there are characteristics that suggest that early-onset CRC may have a different molecular basis. The purpose of this review is to analyze the current state of knowledge about early-onset CRC with respect to clinic-pathological, familial and molecular features. Together, these features make it increasingly clear that this subset of CRC may be a separate disease, although it has much in common with late- onset CRC.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Keywords**: Early-onset colorectal cancer; Lynch syndrome; Microsatellite instability; CpG island methylator phenotype; Chromosomal instability

**Core tip:** Early-onset colorectal cancer (CRC) is a heterogeneous disease with various molecular alterations, in which different subgroups with different histopathological and familial characteristics can be distinguished. Classification of CRC tumors according to their genetic alterations is important for establishing the molecular bases of the disease, as well as for predicting patient outcomes and developing more individualized treatments.

Osorio Silla I, Rueda D, Rodríguez Y, García JL, Cruz Vigo F, Perea García J. Early-onset colorectal cancer: A separate subset of colorectal cancer. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

Colorectal cancer (CRC) has a great impact on the world population. The estimated incidence is 1.2 million new cases per year. It is the third most common malignancy and the second leading cause of death in developed countries[1-3]. In Spain, colorectal cancer incidence projections for the population in 2015 are about 30000 people (17000 men and 13000 women)[4]. Early-onset CRC accounts for 2%-8% of all CRCs. Furthermore, its incidence in the United States increased by 1.5% per year in men and by 1.6% in women between 1992 and 2005. The growing frequency of CRC in young adults contrasts with the progressive decline of CRC among older people. This underscores the importance of early evaluation in cases of young adults with compatible symptoms[5,6].

The classical model of colorectal carcinogenesis for the adenoma-carcinoma sequence has been evolving since its original formulation[7]. Thanks to advances in our understanding of the molecular mechanisms involved. CRC is, nowadays, described with increasing frequency, according to the molecular characteristic of the presenting phenotype; thus, the molecular classification of CRC is gaining importance[8]. Particularly, studies analyzing the possible basis of early-onset CRC have evolved: in early studies the principle prevailed that early-onset is an indicator of a hereditary component[9,10], whereas currently the concept prevails that it is a heterogeneous disease, which includes cases with a strong familial component as well as cases of sporadic disease. Different molecular alterations appear to contribute to the apparent heterogeneity of early-onset CRC and subgroups can be distinguished with distinct histopathological and familial characteristics[11].

The aim of this review is to analyze the current knowledge of the molecular basis of early-onset CRC, and its relationship with the particular clinic-pathologic and familial features of this subset.

**CARCINOGENETIC PATHWAYS OF COLORECTAL CANCER**

To date, three main pathways involved in the formation and development of CRC have been identified: the chromosomal instability (CIN) or suppressor pathway; the microsatellite instability (MSI) or mutator pathway; and the CpG island methylator phenotype (CIMP) or serrated pathway (Table 1). These three pathways differ from the clinic-pathologic, familial and prognostic points of view. While they are overlapping, they are the dominant mechanisms that determines the final phenotype[12].

Most sporadic CRCs (80%-85%) involve the CIN pathway, which is characterized by alterations in the number and structure of chromosomes and frequent loss of heterozygosity (LOH). Cases of familial adenomatous polyposis with germline mutations in the *APC* gene also show CIN; these tumors are also referred to as having microsatellite stability (MSS). Genetic changes include the activation of proto-oncogenes such as *KRAS* and *C-MYC* and inactivation of the tumor suppressor genes, *APC*, and *p53*, and LOH for the long arm of chromosome 18. Recently, mutations in the genes *TGFBR* and *PIK3CA* have been described, which are involved in the adenoma-carcinoma sequence[3,13-16].

MSI tumors, whose carcinogenetic pathway is also known as the “Mutator Phenotype pathway”, represent 10%-15% of all CRCs. MSI is due to an inability of the DNA nucleotide mismatch repair (MMR) system to correct errors that often occur during DNA replication, which is controlled by several genes (including *MLH1, MSH2, MSH6* and *PMS2)* and is characterized by the accumulation of single nucleotide mutations and alterations in the lengths of repetitive microsatellite nucleotide sequences[15,17,18]. Apart from genes related with the DNA nucleotide mismatch repair system, other tumor suppressor genes such as *TGF-βRII, IGFIIR, MSH3* and *BAX* have been described to be involved[19]. MSI tumors are present in two CRC forms: hereditary forms such as Lynch syndrome (LS), the molecular basis of which is a germline mutation in a mismatch repair gene; and sporadic cases, in which MSI is due to hypermethylation of *MLH1*[20]. MSI tumors are characterized by a more frequent location in the right colon, increased mucin production, the presence of signet ring cells and low-grade tumor differentiation[18].

Analysis of methylation of CpG islands as a mechanism of silencing genes in colon tumors has resulted in the identification of a third major pathway (CIMP), which accounts for almost 40% of CRCs[21-23]. This carcinogenetic mechanism is also known as the “serrated pathway”, because CRCs of this subset often arise from a serrated precursor lesion. CIMP-high tumors have a distinct clinical, pathological, and molecular profile, such as association with proximal location in the colon, female sex, and poor differentiation. From the molecular point of view, they show a higher frequency of *BRAF* mutations, MSI and, albeit less often, *P53* mutations[13,24,25].

Until recently, only MSI tumors were thought to be CIN-, and CIN+ tumors were thought to have an intact MMR system and to show MSS. However, several studies have demonstrated that up to 50% of MSS tumors are CIN- (also called microsatellite and chromosome-stable or MACS tumors), and a significant, but smaller, portion of MSI colorectal tumors are CIN+. MACS tumors are being characterized and some of their features are preference for distal colon and rectum, histological features associated with poor prognosis, and more frequent identification in younger cases[26,27].

**MOLECULAR CLASSIFICATION**

As mentioned previously, carcinogenesis pathways are not mutually exclusive. Classification of CRC tumors according to the genetic and/or epigenetic alterations observed is important to establish the molecular bases of the disease, as well as to predict patient outcomes and to develop more individualized treatments. For this reason, a molecular classification has been gaining strength that is based on the three global cellular events (CIN, MSI and CIMP) and reflects underlying mechanisms of carcinogenesis; it correlates with some phenotypic characteristics, as described in our previously published study[28]. Globally, sporadic CRC should be classified into four major subtypes: two MSI statuses (MSI-H *vs* MSI-L/MSS) times two CIMP statuses (CIMP-H *vs* CIMP-low/0), with distinct molecular correlates (BRAF, KRAS) and pathological features[8].

In Table 2 the main features are summarized that define each category[8,15].

**EARLY- ONSET COLORECTAL CANCER**

***Clinicopathological characteristics***

Currently, there are some controversial aspects to the natural history and prognosis of early-onset CRC, and there are also some clinical and pathological differences when comparing with CRC in the elderly[9,29].

Mucinous and signet ring cell tumors account for 10%-15% and 1% of all CRCs, respectively. Several reports indicate that early-onset CRC is clinically and pathologically characterized by a predominance of low grade tumor differentiation, mucinous tumors, and a higher percentage of signet ring cells; these features are shared with hereditary CRC forms[9,30,31]. In addition, some studies have found a relationship between mucinous CRC and poor prognosis[32-34]. Early-onset CRC is associated with a higher percentage of synchronous and/or metachronous tumors, as well as with, an increased development of polyps during follow up[10,35]. Studies addressing the early-onset group within CRC showed important variations concerning tumor location. Some of them found a striking predilection for the distal colon, particularly the sigmoid colon and rectum[33,36]; furthermore, recent studies show an increased incidence of rectal cancer in adults younger than 50 years[34,37]. However, in other series the highest percentage of CRC was seen in the right colon, and, a greater proportion of patients had a family history of CRC, suggesting that CCR in the proximal colon in young patients may reflect a genetic predisposition[30,31].

Generally, early-onset CRC is diagnosed in advanced stages. One reason that could explain this is the absence of screening programs for CRC in patients under 50 years, except in cases of family or personal history of cancer[38]. On the other hand, the aggressive histopathological characteristics of the tumor and a possible genetic basis may predispose to accelerated development of this tumor in young patients[39,40]. Regarding reports in the literature, there are studies showing that CRCs in young patients have poor outcome[32,39]. However, other series found equivalent survival rates in younger patients with CRC compared with older patients, despite presenting a more advanced stage of disease[41]. These discrepancies may be explained by the inclusion of hereditary CRC, particularly LS, which has a better survival rate than sporadic CRC in young patients[42]. The review by Chang et al.[33] shows that early-onset CRC, despite having histologic features that are related to worse prognosis, presents overall survival rates and disease-free survival similar to those seen in patients over 40, but in contrast also has a higher incidence of recurrence and development of distant metastases. These results agree with those published by Yeo *et al*[43], with a median survival at five years in their series of 59.4 % in patients under 40 years and of 61.1% in patients older than 40, while the rate of metastases and locoregional recurrence was greater in the young group.

***Familial characteristics***

Early-onset CRC includes cases with strong familial history and cases with sporadic disease. It is well-known that in this population identification of cases of LS is more likely, even more so when the age of onset is younger[11,44,45]. Apart from that, the familial component within this age of onset group is so important, that when we leave aside LS, there is still a clear familial component in this population: Compared to elderly MSS CRC, early onset CRCs with the same component show more familial aggregation and Lynch-type tumors, a fact that may be related to new hereditary CRC syndromes, such as Familial CRC syndrome type X[46-49].

***Molecular characteristics***

From a molecular point of view, two main aspects have been addressed among the subset of early-onset CRCs: on the one hand, the analysis of proportions of cases with MSI and the necessary relationship with LS, and on the other hand cases with molecular alterations that relate to carcinogenesis pathways associated with CIN.

***MSI analysis: Lynch syndrome and sporadic cases***

Early-onset of cancer is a marker of a potentially hereditary component, with LS being the most frequent hereditary form of CRC. Nevertheless, the proportion of MSI tumors found within early-onset CRC varies from 19.7% to 41%, depending on the age of onset. As shown in Table 3, MSI frequency is inversely proportional to the age at diagnosis and directly proportional to the LS component of the series[9,10,11,48,50-52]. In our recent study, twelve out of 82 early-onset cases were defined as MSI (15%)[28]. In all cases, MSI correlated with lack of detectable expression of any of the MMR proteins in immunohistochemical analysis and 83% of them were explained by a mutation in one of the MMR genes. Moreover, we later confirmed that MSI tumors in the younger population are mostly related to LS and rarely due to somatic inactivation of *MLH1*[28], showing that the criterion of early age of onset, together with other clinicopathological and familial features, is helpful in identifying LS cases[11]. By contrast, diagnosis of LS in [early-onset CRC is highly unlikely in patients with certain combinations of clinical and, familial features: *e.g.,* left sided CRC and absence of family history[49].](http://www.ncbi.nlm.nih.gov/pubmed/24383517)

As expected, early-onset MSI CRC shows some clinical and pathological features similar to those described for LS: more frequent right-sided colon tumors, frequently poorly differentiated tumors showing mucin production and signet ring cells, and a more frequent development of synchronous and metachronous tumors[42,53,54]. Prognosis for MSI tumors is better than for MSS tumors, and since MSI tumors are hypermutated, mutation rate may be a better prognostic indicator for this age of onset[27,42,55,56].

***Chromosomal instability analysis***

The majority of early-onset CRC are MSS tumors, and there are few studies that evaluate the clinicopathological features of this subset of CRC within the early-onset population[46,57,58]. MSS tumors are characterized by a later age of onset, lower prevalence in the right colon and fewer synchronous and metachronous tumors; they also tend to be diagnosed at later stages and more frequently show adverse histologic features[33]. Compared with late-onset cases showing MSS, early-onset MSS tumors are remarkably different from those late-onset cases, as highlighted by the important rate of left colon location, low frequently of other primary neoplasms and the presence of an important familial component[24,28,46] .

We previously pointed out the importance of age of onset to make an appropriate approach to the molecular classification of CRC, given the possible different molecular basis of early onset CRC compared with elderly CRC[28]. Apart from some preliminarily defined molecular markers (modified expression of the APC, B-catenin and P53 genes), new findings have been reported about MSS early-onset CRC[59]. The main emerging key aspects are: (1) Analysis of MACS tumors. These tumors, particularly when they are located in rectum, appear to have longer telomeres than those of MSS CIN rectal cancers and use alternative lengthening of telomeres rather than activation of telomerase[60]; and (2) The use of high resolution tumor genome copy number variations in order to identify differences in the tumor genomes between these groups and to pinpoint potential susceptibility loci. Comparing two MSS CRC groups with different ages of onset, Berg et al[61] identified ten genomic loci, containing more than 500 protein-coding genes, as more often altered in tumors from early-onset vs late-onset CRC. In addition integration of genome and transcriptome data identified seven novel candidate genes with the potential to identify an increased risk for CRC[61].

***CIMP analysis***

CIMP has been rarely evaluated within early-onset CRC. Previous large series, without using age of onset as a differential criterion, showed that LS cases were mainly included in the CIMP-low group, while sporadic MSI cases were more likely to be CIMP-high, with high rates of *BRAF* mutations[8]. Nevertheless, these features are observed within the late-onset CRC group, while in early-onset CRC LS primarily has a higher percentage within the CIMP-high group. This could be the consequence, among others, of a low number of *BRAF* mutations and hypermethylation of the *MLH1* promoter in early-onset CRC[28,36,57,58]. It is known that the difference between CIMP-low and CIMP-0 is unclear when considering CRC in general. Within the early-onset population, a number of differences with the elderly group draw the attention: a progressive disappearance of right colon tumors, a higher rate of CIMP-low cases and an important familial component: LS-related tumors, but also cancer history is observed in case of CIMP-low or CIMP-0, with an important number of LS-related neoplasias[28].

***Microsatellite and chromosomal stable tumors***

Some tumors with MSS have recently been identified that, contrary to expectations, do not have CIN. Furthermore, they do not strictly fit with tumors involving the serrated pathway. This subset of CRC, defined as MACS, is identified most frequently in younger cases. It is also more frequently observed in the distal colon and rectum, has histological features associated with poor prognosis and some familial aggregation for LS neoplasms[47]. MACS tumors also, present metastases at diagnosis[46,62]. Banerjea *et al*[62] showed that patients with MACS tumors had early disease recurrence and less survival than patients with MSI or CIN tumors. This important circumstance is due to a diminished or inhibited immune response to MACS tumors in comparison with other CRC phenotypes[62]. Regarding family characteristics, some published studies conclude that MACS may be related to familial CRC syndromes, based on an observed increased frequency in young patients with family history. However, other studies illustrate that MSS and CIN CRCs are not necessarily related to hereditary tumors[47,63]. Little is known about MACS from a molecular point of view, but it seems that these tumors have a different methylation profile that involves genes not known to be involved in global CCR. Several studies have found that MACS tumors are associated with CIMP low, that they rarely have *BRAF* gene mutations and absent *MLH1* expression, and they seem to have a different pattern of hypomethylation when compared to MSI and CIN CRC. This has raised the possibility that LINE 1 hypomethylation may be related to MACS[64,66]. Recently, LINE-1 hypomethylation has been shown to be a feature of young age of onset of CRC, and it is also associated with family history of CRC. According to the molecular classification of CRC, CIMP-high and MSI-high are inversely associated, while MSS tumors are correlated with LINE-1 hypomethylation, and genomic hypomethylation may represent different pathways to CRC[67].

***Molecular classification***

The first classification of CRC to correlate the main molecular carcinogenetic pathways was proposed by Jass[68], and was latermodified by Ogino and Goel[8]. Based on MSI and CIMP status, CRC should be classified into four major subsets, with some features particular for each one, as has been described previously.

Perea *et al*[28] carried out a comparative analysis of MSI status and CIMP in two series of early-onset and late-onset CRCs, in order to evaluate molecular classification according to age of onset. It was the first study that characterized early-onset CRC based on its molecular classification, and the main differences found, compared with the features of previously described global CRC, were: (1) early-onset MSI/CIMP-high tumors were Lynch tumors, whereas elderly MSI/CIMP-high tumors were associated with *BRAF* mutations; (2) half of early-onset MSI/CIMP-low/0 cases were Lynch tumors with a mucinous component and were left-sided. According to these results, the early-onset criterion would make a change in the MSI groups of Ogino and Goel’s molecular classification[8], particularly in MSI/CIMP-high tumors, because they would contain the main proportion of LS within early-onset MSI CRC[28,36,57]; (3) the MSS/CIMP-high category had more similarities, although there was a remarkably important familial component in the early-onset subset of tumors, mainly regarding LS-related neoplasm aggregation; and (4) the most common group within the early-onset population was formed by MSS/CIMP-low/0 tumors, showing a preference for the distal colon and containing an important familial cancer component.

***Location characteristics***

Several studies suggest that tumor location is one of the most influential factors of CRC morphology. When comparing the characteristics of CRCs according to their location, differences are observed in terms of epidemiological, clinicopathological, familial, genetic and risk factors[69,73]. Increasingly, it is suggested that these differences between tumors of the right and the left side of the colon and the rectum may be due to differences in embryological origin, or to different physiological, biological and gene expression properties. This would condition different carcinogenetic pathways depending on the location in one or another region of the colon[71,72,75].

To our knowledge, to date there are no published studies that examine the phenotype of CRC in young adults according to the location of the tumor. Globally, cancer of the right colon is frequently observed in the elderly and in women, while cancer of the left colon predominates in young people and in men[69,75-79]. Indeed, several studies show an increased incidence of rectal cancer in patients younger than 50 years[34,37]. Regarding histopathological features, tumors in the right colon have been associated with low degree of differentiation and a higher frequency of signet ring cells and mucin production when compared to left and rectum tumors. These characteristics are also described for early-onset CRC[66,73]. Regarding family characteristics, neoplasms located in the right colon are more frequently associated with LS[48,50,80]. However, some studies draw attention to the high percentage of cases with a family history of tumors located in the rectum and left colon within early-onset CRC[28]. These cases could be related, as mentioned previously, to new hereditary syndromes whose molecular basis and phenotypic characteristics are not yet known, such as Familial CRC syndrome type X[46,47,48,49] .

Finally, knowledge of the molecular characteristics of early-onset tumors at different locations in the colon is limited. Regardless of the age of onset, Bufill[70] suggested that proximal colon cancers and distal CRCs have arisen through different genetic pathways. Subsequently, different studies described the preference of CIMP and MSI in proximal colon cancer and of CIN and P53 mutation in distal and rectal cancer[56,81,82]. In our recent study that analyzed 88 young patients with CRC, we observed a gradual decrease in the frequencies of CIMP and MSI when going from the proximal colon through the left colon to the rectum, and increased frequencies of MACS in the distal colon and rectum[83]. Our results agree with those previously described by other authors[73].

**CONCLUSION**

Although early age of onset is a criterion used to identify hereditary CRC, several studies have observed that a significant percentage of cases within this population have MSS tumors. In addition, MACS tumors are present in a substantial proportion. Moreover, when we analyzed the three main molecular pathways and their phenotypical features in early-onset CRC, we observed striking differences between these tumors and late-onset tumors. The theoretical existence of different molecular bases, mainly suggested by the heterogeneous MSS CRC group, has already opened an important new field of research aimed at finding related candidate susceptibility loci. Taken together, these observations support the increasingly clear possibility that early-onset CRC may be a different disease than late-onset CRC, even though they have much in common.

This integrated view of molecular alterations, their associations with disease phenotype and their implications in tumor progression and development will allow a better understanding of the physio-pathology of CRC and, the identification of new therapeutic targets, and lead to more individualized patient management, in this case, according to the age of onset.

**ACKNOWLEDGEMENTS**

We thank Ron Hartong for his help with the English redaction of the article.

**REFERENCES**

1 **Jemal A**, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]

2 **Ferlay J**, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; **127**: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]

3 **Sameer AS**. Colorectal cancer: molecular mutations and polymorphisms. *Front Oncol* 2013; **3**: 114 [PMID: 23717813 DOI: 10.3389/fonc.2013.00114]

4 Sociedad española de oncología médica. Las cifras del cáncer en España 2014. Available from: http://www.seom.org/seomcms/images/stories/recursos/Las\_cifras\_del\_cancer\_2014.pdf

5 **Boyle P**, Ferlay J. Cancer incidence and mortality in Europe, 2004. *Ann Oncol* 2005; **16**: 481-488 [PMID: 15718248]

6 **Siegel RL**, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. *Cancer Epidemiol Biomarkers Prev* 2009; **18**: 1695-1698 [PMID: 19505901 DOI: 10.1158/1055-9965]

7 **Fearon ER**, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 1990; **61**: 759-767 [PMID: 2188735]

8 **Ogino S**, Goel A. Molecular classification and correlates in colorectal cancer. *J Mol Diagn* 2008; **10**: 13-27 [PMID: 18165277 DOI: 10.2353/jmoldx.2008.070082]

9 **Losi L**, Di Gregorio C, Pedroni M, Ponti G, Roncucci L, Scarselli A, Genuardi M, Baglioni S, Marino M, Rossi G, Benatti P, Maffei S, Menigatti M, Roncari B, Ponz de Leon M. Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes. *Am J Gastroenterol* 2005; **100**: 2280-2287 [PMID: 16181381]

10 **Liang JT**, Huang KC, Cheng AL, Jeng YM, Wu MS, Wang SM. Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. *Br J Surg* 2003; **90**: 205-214 [PMID: 12555297]

11 **Perea J**, Rodríguez Y, Rueda D, Marín JC, Díaz-Tasende J, Álvaro E, Alegre C, Osorio I, Colina F, Lomas M, Hidalgo M, Benítez J, Urioste M. Early-onset colorectal cancer is an easy and effective tool to identify retrospectively Lynch syndrome. *Ann Surg Oncol* 2011; **18**: 3285-3291 [PMID: 21590452 DOI: 10.1245/s10434-011-1782-4]

12 **de la Chapelle A**. Microsatellite instability. *N Engl J Med* 2003; **349**: 209-210 [PMID: 12867603]

13 **Armaghany T**, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. *Gastrointest Cancer Res* 2012; **5**: 19-27 [PMID: 22574233]

14 **Pino MS**, Chung DC. The chromosomal instability pathway in colon cancer. *Gastroenterology* 2010; **138**: 2059-2072 [PMID: 20420946 DOI: 10.1053/j.gastro.2009.12.065]

15 **Sameer AS**, Nissar S, Fatima K. Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis. *Eur J Cancer Prev* 2014; **23**: 246-257 [PMID: 24614649 DOI: 10.1097/CEJ.0000000000000019]

16 **Migliore L**, Migheli F, Spisni R, Coppedè F. Genetics, cytogenetics, and epigenetics of colorectal cancer. *J Biomed Biotechnol* 2011; **2011**: 792362 [PMID: 21490705 DOI: 10.1155/2011/792362]

17 **Peltomäki P**. Role of DNA mismatch repair defects in the pathogenesis of human cancer. *J Clin Oncol* 2003; **21**: 1174-1179 [PMID: 12637487]

18 **Cunningham D**, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. *Lancet* 2010; **375**: 1030-1047 [PMID: 20304247 DOI: 10.1016/S0140-6736(10)60353-4]

19 **Raut CP**, Pawlik TM, Rodriguez-Bigas MA. Clinicopathologic features in colorectal cancer patients with microsatellite instability. *Mutat Res* 2004; **568**: 275-282 [PMID: 15542114]

20 **Grady WM**. Genomic instability and colon cancer. *Cancer Metastasis Rev* 2004; **23**: 11-27 [PMID: 15000146]

21 **van Rijnsoever M**, Grieu F, Elsaleh H, Joseph D, Iacopetta B. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. *Gut* 2002; **51**: 797-802 [PMID: 12427779]

22 **Samowitz WS**, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK, Slattery ML. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. *Gastroenterology* 2005; **129**: 837-845 [PMID: 16143123]

23 **Issa JP**. CpG island methylator phenotype in cancer. *Nat Rev Cancer* 2004; **4**: 988-993 [PMID: 15573120]

24 **Snover DC**. Update on the serrated pathway to colorectal carcinoma. *Hum Pathol* 2011; **42**: 1-10 [PMID: 20869746 DOI: 10.1016/j.humpath.2010.06.002]

25 **Nazemalhosseini Mojarad E**, Kuppen PJ, Aghdaei HA, Zali MR. The CpG island methylator phenotype (CIMP) in colorectal cancer. *Gastroenterol Hepatol Bed Bench* 2013; **6**: 120-128 [PMID: 24834258]

26 **Tang R**, Changchien CR, Wu MC, Fan CW, Liu KW, Chen JS, Chien HT, Hsieh LL. Colorectal cancer without high microsatellite instability and chromosomal instability--an alternative genetic pathway to human colorectal cancer. *Carcinogenesis* 2004; **25**: 841-846 [PMID: 14729584]

27 **Sinicrope FA**, Rego RL, Halling KC, Foster N, Sargent DJ, La Plant B, French AJ, Laurie JA, Goldberg RM, Thibodeau SN, Witzig TE. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. *Gastroenterology* 2006; **131**: 729-737 [PMID: 16952542]

28 **Perea J**, Rueda D, Canal A, Rodríguez Y, Álvaro E, Osorio I, Alegre C, Rivera B, Martínez J, Benítez J, Urioste M. Age at onset should be a major criterion for subclassification of colorectal cancer. *J Mol Diagn* 2014; **16**: 116-126 [PMID: 24184227 DOI: 10.1016/j.jmoldx.2013.07.010]

29 **Fairley TL**, Cardinez CJ, Martin J, Alley L, Friedman C, Edwards B, Jamison P. Colorectal cancer in U.S. adults younger than 50 years of age, 1998-2001. *Cancer* 2006; **107**: 1153-1161 [PMID: 16862554]

30 **Mahdavinia M**, Bishehsari F, Ansari R, Norouzbeigi N, Khaleghinejad A, Hormazdi M, Rakhshani N, Malekzadeh R. Family history of colorectal cancer in Iran. *BMC Cancer* 2005; **5**: 112 [PMID: 16143045]

31 **Savas N**, Dagli U, Akbulut S, Yuksel O, Sahin B. Colorectal cancer localization in young patients: should we expand the screening program? *Dig Dis Sci* 2007; **52**: 798-802 [PMID: 17245629]

32 **da Fonseca LM**, da Luz MM, Lacerda-Filho A, Cabral MM, da Silva RG. Colorectal carcinoma in different age groups : a histopathological analysis. *Int J Colorectal Dis* 2012; **27**: 249-255 [PMID: 21845417 DOI: 10.1007/s00384-011-1299-0]

33 **Chang DT**, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. *Mod Pathol* 2012; **25**: 1128-1139 [PMID: 22481281 DOI: 10.1038/modpathol.2012.61]

34 **You YN**, Dozois EJ, Boardman LA, Aakre J, Huebner M, Larson DW. Young-onset rectal cancer: presentation, pattern of care and long-term oncologic outcomes compared to a matched older-onset cohort. *Ann Surg Oncol* 2011; **18**: 2469-2476 [PMID: 21448750 DOI: 10.1245/s10434-011-1674-7]

35 **Perea J**, Alvaro E, Rodríguez Y, Gravalos C, Sánchez-Tomé E, Rivera B, Colina F, Carbonell P, González-Sarmiento R, Hidalgo M, Urioste M. Approach to early-onset colorectal cancer: clinicopathological, familial, molecular and immunohistochemical characteristics. *World J Gastroenterol* 2010; **16**: 3697-3703 [PMID: 20677343]

36 **Giráldez MD**, López-Dóriga A, Bujanda L, Abulí A, Bessa X, Fernández-Rozadilla C, Muñoz J, Cuatrecasas M, Jover R, Xicola RM, Llor X, Piqué JM, Carracedo A, Ruiz-Ponte C, Cosme A, Enríquez-Navascués JM, Moreno V, Andreu M, Castells A, Balaguer F, Castellví-Bel S. Susceptibility genetic variants associated with early-onset colorectal cancer. *Carcinogenesis* 2012; **33**: 613-619 [PMID: 22235025 DOI: 10.1093/carcin/bgs009]

37 **Yantiss RK**, Goodarzi M, Zhou XK, Rennert H, Pirog EC, Banner BF, Chen YT. Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. *Am J Surg Pathol* 2009; **33**: 572-582 [PMID: 19047896 DOI: 10.1097/PAS]

38 **Castells A**, Marzo-Castillejo M, Mascort JJ, Amador FJ, Andreu M, Bellas B, Ferrández A, Ferrándiz J, Giráldez M, Gonzalo V, Jover R, Quintero E, Alonso-Coello P, Bonfill X, Lanas A, Piñol V, Piqué J. [Clinical practice guideline. Prevention of colorectal cancer. 2009 update. Asociación Española de Gastroenterología]. *Gastroenterol Hepatol* 2009; **32**: 717.e1-717.58 [PMID: 20474100]

39 **Lin JT**, Wang WS, Yen CC, Liu JH, Yang MH, Chao TC, Chen PM, Chiou TJ. Outcome of colorectal carcinoma in patients under 40 years of age. *J Gastroenterol Hepatol* 2005; **20**: 900-905 [PMID: 15946138]

40 **Calin GA**, Gafà R, Tibiletti MG, Herlea V, Becheanu G, Cavazzini L, Barbanti-Brodano G, Nenci I, Negrini M, Lanza G. Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: A study of the TGRbetaRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes. *Int J Cancer* 2000; **89**: 230-235 [PMID: 10861498]

41 **O'Connell JB**, Maggard MA, Liu JH, Etzioni DA, Ko CY. Are survival rates different for young and older patients with rectal cancer? *Dis Colon Rectum* 2004; **47**: 2064-2069 [PMID: 15657655]

42 **Popat S**, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. *J Clin Oncol* 2005; **23**: 609-618 [PMID: 15659508]

43 **Yeo SA**, Chew MH, Koh PK, Tang CL. Young colorectal carcinoma patients do not have a poorer prognosis: a comparative review of 2,426 cases. *Tech Coloproctol* 2013; **17**: 653-661 [PMID: 23460362 DOI: 10.1007/s10151-013-0977-z]

44 **Jasperson KW**, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. *Gastroenterology* 2010; **138**: 2044-2058 [PMID: 20420945 DOI: 10.1053/j.gastro.2010.01.054]

45 **Pucciarelli S**, Agostini M, Viel A, Bertorelle R, Russo V, Toppan P, Lise M. Early-age-at-onset colorectal cancer and microsatellite instability as markers of hereditary nonpolyposis colorectal cancer. *Dis Colon Rectum* 2003; **46**: 305-312 [PMID: 12626904]

46 **Hawkins NJ**, Tomlinson I, Meagher A, Ward RL. Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. *Br J Cancer* 2001; **84**: 232-236 [PMID: 11161382]

47 **Chan TL**, Curtis LC, Leung SY, Farrington SM, Ho JW, Chan AS, Lam PW, Tse CW, Dunlop MG, Wyllie AH, Yuen ST. Early-onset colorectal cancer with stable microsatellite DNA and near-diploid chromosomes. *Oncogene* 2001; **20**: 4871-4876 [PMID: 11521198]

48 **Valle L**, Perea J, Carbonell P, Fernandez V, Dotor AM, Benitez J, Urioste M. Clinicopathologic and pedigree differences in amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status. *J Clin Oncol* 2007; **25**: 781-786 [PMID: 17228022]

49 **Stigliano V**, Sanchez-Mete L, Martayan A, Diodoro M, Casini B, Sperduti I, Anti M. Early-onset colorectal cancer patients without family history are "at very low risk" for lynch syndrome. *J Exp Clin Cancer Res* 2014; **33**: 1 [PMID: 24383517 DOI: 10.1186/1756-9966-33-1]

50 **Jasperson KW**, Vu TM, Schwab AL, Neklason DW, Rodriguez-Bigas MA, Burt RW, Weitzel JN. Evaluating Lynch syndrome in very early onset colorectal cancer probands without apparent polyposis. *Fam Cancer* 2010; **9**: 99-107 [PMID: 19731080 DOI: 10.1007/s10689-009-9290-4]

51 **Durno C**, Aronson M, Bapat B, Cohen Z, Gallinger S. Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma. *Gut* 2005; **54**: 1146-1150 [PMID: 15845562 DOI: 10.1136/gut.2005.066092]

52 **Farrington SM**, Lin-Goerke J, Ling J, Wang Y, Burczak JD, Robbins DJ, Dunlop MG. Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and controls. *Am J Hum Genet* 1998; **63**: 749-759 [PMID: 9718327 DOI: 10.1086/301996]

53 **Vasen HF**, Wijnen J. Clinical implications of genetic testing of hereditary nonpolyposis colorectal cancer. *Cytogenet Cell Genet* 1999; **86**: 136-139 [PMID: 10545704]

54 **Chiang JM**, Chen MC, Changchien CR, Chen JS, Tang R, Wang JY, Yeh CY, Fan CW, Tsai WS. Favorable influence of age on tumor characteristics of sporadic colorectal adenocarcinoma: patients 30 years of age or younger may be a distinct patient group. *Dis Colon Rectum* 2003; **46**: 904-910 [PMID: 12847364]

55 **Gryfe R**, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. *N Engl J Med* 2000; **342**: 69-77 [PMID: 10631274]

56 Comprehensive molecular characterization of human colon and rectal cancer. *Nature* 2012; **487**: 330-337 [PMID: 22810696 DOI: 10.1038/nature11252]

57 **Goel A**, Nagasaka T, Spiegel J, Meyer R, Lichliter WE, Boland CR. Low frequency of Lynch syndrome among young patients with non-familial colorectal cancer. *Clin Gastroenterol Hepatol* 2010; **8**: 966-971 [PMID: 20655395 DOI: 10.1016/j.cgh.2010.06.030]

58 **van Roon EH**, van Puijenbroek M, Middeldorp A, van Eijk R, de Meijer EJ, Erasmus D, Wouters KA, van Engeland M, Oosting J, Hes FJ, Tops CM, van Wezel T, Boer JM, Morreau H. Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? *BMC Cancer* 2010; **10**: 180 [PMID: 20444249 DOI: 10.1186/1471-2407-10-180]

59 **Yiu R**, Qiu H, Lee SH, García-Aguilar J. Mechanisms of microsatellite instability in colorectal cancer patients in different age groups. *Dis Colon Rectum* 2005; **48**: 2061-2069 [PMID: 16374936]

60 **Boardman LA**, Johnson RA, Viker KB, Hafner KA, Jenkins RB, Riegert-Johnson DL, Smyrk TC, Litzelman K, Seo S, Gangnon RE, Engelman CD, Rider DN, Vanderboom RJ, Thibodeau SN, Petersen GM, Skinner HG. Correlation of chromosomal instability, telomere length and telomere maintenance in microsatellite stable rectal cancer: a molecular subclass of rectal cancer. *PLoS One* 2013; **8**: e80015 [PMID: 24278232 DOI: 10.1371/journal.pone.0080015]

61 **Berg M**, Agesen TH, Thiis-Evensen E, Merok MA, Teixeira MR, Vatn MH, Nesbakken A, Skotheim RI, Lothe RA. Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci. *Mol Cancer* 2010; **9**: 100 [PMID: 20459617 DOI: 10.1186/1476-4598-9-100]

62 **Banerjea A**, Hands RE, Powar MP, Bustin SA, Dorudi S. Microsatellite and chromosomal stable colorectal cancers demonstrate poor immunogenicity and early disease recurrence. *Colorectal Dis* 2009; **11**: 601-608 [PMID: 18637931 DOI: 10.1111/j.1463-1318.2008.01639.x]

63 **Rex DK**, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, Goldblum JR, Guillem JG, Kahi CJ, Kalady MF, O'Brien MJ, Odze RD, Ogino S, Parry S, Snover DC, Torlakovic EE, Wise PE, Young J, Church J. Serrated lesions of the colorectum: review and recommendations from an expert panel. *Am J Gastroenterol* 2012; **107**: 1315-129; quiz 1314, 1330 [PMID: 22710576 DOI: 10.1038/ajg.2012.161]

64 **Cai G**, Xu Y, Lu H, Shi Y, Lian P, Peng J, Du X, Zhou X, Guan Z, Shi D, Cai S. Clinicopathologic and molecular features of sporadic microsatellite- and chromosomal-stable colorectal cancers. *Int J Colorectal Dis* 2008; **23**: 365-373 [PMID: 18193434 DOI: 10.1007/s00384-007-0423-7]

65 **Silver A**, Sengupta N, Propper D, Wilson P, Hagemann T, Patel A, Parker A, Ghosh A, Feakins R, Dorudi S, Suraweera N. A distinct DNA methylation profile associated with microsatellite and chromosomal stable sporadic colorectal cancers. *Int J Cancer* 2012; **130**: 1082-1092 [PMID: 21455990 DOI: 10.1002/ijc.26104]

66 **Antelo M**, Balaguer F, Shia J, Shen Y, Hur K, Moreira L, Cuatrecasas M, Bujanda L, Giraldez MD, Takahashi M, Cabanne A, Barugel ME, Arnold M, Roca EL, Andreu M, Castellvi-Bel S, Llor X, Jover R, Castells A, Boland CR, Goel A. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. *PLoS One* 2012; **7**: e45357 [PMID: 23049789 DOI: 10.1371/journal.pone.0045357]

67 **Baba Y**, Huttenhower C, Nosho K, Tanaka N, Shima K, Hazra A, Schernhammer ES, Hunter DJ, Giovannucci EL, Fuchs CS, Ogino S. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. *Mol Cancer* 2010; **9**: 125 [PMID: 20507599 DOI: 10.1186/1476-4598-9-125]

68 **Jass JR**. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. *Histopathology* 2007; **50**: 113-130 [PMID: 17204026]

69 **Snaebjornsson P**, Jonasson L, Jonsson T, Möller PH, Theodors A, Jonasson JG. Colon cancer in Iceland--a nationwide comparative study on various pathology parameters with respect to right and left tumor location and patients age. *Int J Cancer* 2010; **127**: 2645-2653 [PMID: 20162576 DOI: 10.1002/ijc.25258]

70 **Bufill JA**. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. *Ann Intern Med* 1990; **113**: 779-788 [PMID: 2240880]

71 **Li FY**, Lai MD. Colorectal cancer, one entity or three. *J Zhejiang Univ Sci B* 2009; **10**: 219-229 [PMID: 19283877 DOI: 10.1631/jzus.B0820273]

72 **Benedix F**, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. *Dis Colon Rectum* 2010; **53**: 57-64 [PMID: 20010352 DOI: 10.1007/DCR.0b013e3181c703a4]

73 **Yamauchi M**, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs C, Ogino S. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. *Gut* 2012; **61**: 847-854 [PMID: 22427238 DOI: 10.1136/gutjnl-2011-300865]

74 **Glebov OK**, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, DeNobile J, Soballe P, Simon R, Wright G, Lynch P, Patterson S, Lynch H, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR. Distinguishing right from left colon by the pattern of gene expression. *Cancer Epidemiol Biomarkers Prev* 2003; **12**: 755-762 [PMID: 12917207]

75 **Iacopetta B**. Are there two sides to colorectal cancer? *Int J Cancer* 2002; **101**: 403-408 [PMID: 12216066]

76 **Nawa T**, Kato J, Kawamoto H, Okada H, Yamamoto H, Kohno H, Endo H, Shiratori Y. Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. *J Gastroenterol Hepatol* 2008; **23**: 418-423 [PMID: 17532785]

77 **Gonzalez EC**, Roetzheim RG, Ferrante JM, Campbell R. Predictors of proximal vs. distal colorectal cancers. *Dis Colon Rectum* 2001; **44**: 251-258 [PMID: 11227943]

78 **McCashland TM**, Brand R, Lyden E, de Garmo P. Gender differences in colorectal polyps and tumors. *Am J Gastroenterol* 2001; **96**: 882-886 [PMID: 11280569]

79 **Bae JM**, Kim JH, Cho NY, Kim TY, Kang GH. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. *Br J Cancer* 2013; **109**: 1004-1012 [PMID: 23900220 DOI: 10.1038/bjc.2013.430]

80 **Balmaña J**, Castells A, Cervantes A. Familial colorectal cancer risk: ESMO Clinical Practice Guidelines. *Ann Oncol* 2010; **21 Suppl 5**: v78-v81 [PMID: 20555108]

81 **Weisenberger DJ**, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. *Nat Genet* 2006; **38**: 787-793 [PMID: 16804544]

82 **Ogino S**, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. *Gut* 2009; **58**: 90-96 [PMID: 18832519 DOI: 10.1136/gut.2008.155473]

83 **Álvaro E**, Perea J, Alegre C, García M, Osorio I, Brandáriz L, Rueda D, Urioste M. Diferential features within early-onset colorectal cancer depending on the tumor location. XIX National Congress of Surgery; 2013 Oct 23-25; Burgos, Spain

**P-Reviewer:** Sameer AS, Tiberio GAM **S-Editor:** Gou SX  **L-Editor: E-Editor:**

**Table 1 Main pathways involved in the onset and development of colorectal cancer**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Chromosomal instability or**  **“suppressor” pathway** | **Microsatellite instability or “mutator” pathway** | **CpG island methylator phenotype or “serrated” pathway** |
| % of CRC | 80%-85% | 10%-15% | 40% |
| Clinical characteristics | Predominant location of tumor in the distal colon | Predominant location of tumor in the right colon  Better prognosis | Predominant location of tumor in the right colon  Female sex |
| Histopathological characteristics | No lymphocytic reactions  No mucinous features  Good differentiation | Lymphocytic reactions  Mucinous features  Signet ring cells  Low-grade tumor differentiation | Low-grade tumor differentiation |
| Molecular characteristics | Aneuploidy, polyploidy, loss of heterozygosity | Diploidy, MSI | Methylation of CpG islands |
| Main genes  involved | *APC, P53, KRAS, C-MYC, DCC/SMAD4, TGFBR, PIK3CA* | *MLH1, MSH2,*  *MSH6, PMS2,*  *TGF-βRII, IGFIIR,*  *MSH3* and *BAX* | *BRAF, MSI* |
| Hereditary syndromes | Familial adenomatous polyposis | Lynch syndrome |  |

CRC: Colorectal cancer; MSI: Microsatellite instability.

**Table 2 Main features of molecular classification**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Category** | **CRC** | **Molecular characteristics** | **Histophatological characteristics** | **Clinical characteristics** |
| MSI/CIMP High | 10% | *MLH1* methylation  *BRAF* mutations | Poor differentation  Limphocytic reaction  Mucinous/ signet ring cells | Predominant location of tumor in right colon  Elderly females  Sporadic MSI |
| MSI/CIMP Low/0 | 5% | MMR  Negative for *BRAF* mutations | Lymphocytic reaction  Mucinous features  No signet ring cells  Good or moderate differentation | LS |
| MSS/CIMP High | 5%-10% | *BRAF* mutations and methylation of multiple other genes | Poor differentation  Signet ring cell | Predominant location of tumor in right colon  Elderly females |
| MSS/CIMP Low/0 | 75%-80% | CIN  *KRAS* mutations | Well differentiated  Heterogeneous | Predominant location of tumor in distal colon  Male sex |

MSI: Microsatellite instability; CIMP: CpG island methylator phenotype; MSS: Microsatellite stability; MMR: Mismatch repair; CIN: Chromosomal instability; LS: Lynch syndrome.

**Table 3** **Proportion of microsatellite instability in early-onset colorectal cancers series and their age of onset *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study** | **Age of CRC onset**  **(yr)** | **Population** | **MSI** |
| Losi *et al*[9] | ≤ 45 | Unselected CRC surgical patients | 71 (19.7) |
| Liang *et al*[10] | ≤ 40 | Unselected CRC surgical patients | 138 (40.5) |
| Perea *et al*[11] | ≤ 45 | Unselected CRC surgical patients | 88 (13.6) |
| Jasperson *et al*[50] | < 36 | Hereditary cancer registries | 96 (29.1) |
| Durno *et al*[51] | < 25 | Familial cancer registry | 16 (72.7) |
| Farrington *et al*[52] | < 30 | Cancer registries | 50 (47.5) |
| Antelo *et al*[66] | < 50 | Cancer registry | 118 (22.9) |

CRC: Colorectal cancer; MSI: Microsatellite instability.